Mechanisms of broadly neutralizing humoral immunity against influenza viruses

广泛中和流感病毒体液免疫的机制

• 批准号: 8825401
• 负责人: Peter Palese
• 金额: $ 191.84万
• 依托单位: ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
• 依托单位国家: 美国
• 财政年份: 2014
• 资助国家: 美国
• 起止时间: 2014-04-01 至 2019-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8825401
• 关键词: Antibodies; Antigens; B-Lymphocytes; Binding; Blocking Antibodies; Chicago; Communication; Communities; Data; Dissection; Elements; Epidemic; Epitope Mapping; Epitopes; Evolution; Exhibits; Fc Receptor; Fc domain; Generations; Glycoproteins; HN Protein; Hemagglutinin; Human; Humoral Immunities; IgG1; Immune response; Immunity; Immunization; Immunoglobulin Constant Region; Immunoglobulin G; Influenza; Influenza vaccination; Intention; Intervention; Investigation; Knock-in Mouse; Laboratories; Maintenance; Maps; Mediating; Medicine; Membrane; Membrane Glycoproteins; Membrane Proteins; Memory; Microbiology; Molecular; Molecular Genetics; Molecular Immunology; Monoclonal Antibodies; Mouse Strains; Mus; Neuraminidase; Occupational activity of managing finances; Office of Administrative Management; Pathogenesis; Plasmablast; Polysaccharides; Protein Microchips; Reagent; Recombinants; Regulation; Resistance; Resources; Rheumatology; Role; Route; Specificity; System; Therapeutic; Time; Transgenic Animals; Universities; Vaccination; Vaccine Therapy; Vaccines; Viral; Viral Hemagglutinins; Viral Proteins; Virus; Virus Diseases; Work; anti-influenza; base; bindin; design; expression cloning; flu; human subject; improved; influenza virus vaccine; influenzavirus; medical schools; member; neutralizing monoclonal antibodies; pathogen; polyclonal antibody; public health relevance; recombinant virus; response; success; transmission process; vaccine development

DESCRIPTION (provided by applicant): Human vaccines have most often been generated by trial and error with little understanding of molecular mechanisms involved in the protective immunity that they provide. This system of vaccine development has been remarkably effective against pathogens that exhibit little variability over time; however, it has become evident that a much more sophisticated approach is required to develop broadly protective vaccines against pathogens that undergo continuous structural change, such as influenza viruses. Current influenza virus vaccines confer protection by eliciting antibodies that block viral entry by bindin regions of the virus that are highly mutable. In order for antibody-based therapies and vaccines to be effective against a breadth of structurally diverse influenza viruses, protection will clearl have to be gained through alternate routes of blocking viral replication. The identification of broadly neutralizing monoclonal antibodies against the conserved stalk domain of the viral hemagglutinin (HA), by members of our group and by others, was a groundbreaking advance, as many of these antibodies are able to block fusion of viral and endosomal membranes, yet bind epitopes that are relatively resistant to structural change. A second critical finding by members of our group was that protection mediated by anti-stalk antibodies at low concentrations is dependent on Fc-Fc Receptor (FcR) interactions; therefore, antibody isotype determines protective activity of anti-stalk antibodies at lower concentrations. The current proposal is for a multi-center investigation into molecular mechanisms that can be harnessed to provide broad-based protection against influenza viruses. Our projects include: 1) Precise mapping of epitopes on the viral HA and neuraminidase glycoproteins that mediate virus neutralization, and dissection of mechanisms by which they achieve neutralization. 2) Immunization studies using chimeric influenza virus proteins designed to identify structural elements able to mediate broad-spectrum humoral immunity. 3) Delineation of the roles of Fc-FcR interactions in viral neutralization. 4) Investigation in human subjects into how to elicit antibodies with favorable Fc domains during vaccination. 5) Studies on the natural evolution of human B cell specificities against influenza antigens. 6) Identification of specific sequences of influenza antigen exposures that elicit broad-spectrum, anti-influenza humoral immunity. Overall, our intention is to better understand the mechanisms of broadly protective humoral immune responses against the influenza virus surface proteins and thereby create a blueprint for advancing a new generation of broadly protective influenza virus vaccines and antibody-based therapeutics.

描述（由申请人提供）：人类疫苗通常是通过反复试验而产生的，而对其提供的保护性免疫所涉及的分子机制知之甚少。这种疫苗开发系统对于对抗随时间变化几乎没有变化的病原体非常有效。然而，很明显，需要一种更复杂的方法来开发针对经历持续结构变化的病原体（例如流感病毒）的广泛保护性疫苗。目前的流感病毒疫苗通过引发抗体来提供保护，这些抗体通过高度可变的病毒结合区域阻止病毒进入。为了使基于抗体的疗法和疫苗能够有效对抗多种结构不同的流感病毒，显然必须通过阻断病毒复制的替代途径来获得保护。我们小组的成员和其他人鉴定了针对病毒血凝素（HA）保守茎结构域的广泛中和单克隆抗体，这是一项突破性的进展，因为其中许多抗体能够阻断病毒和内体膜的融合，但结合对结构变化相对抵抗的表位。我们小组成员的第二个重要发现是，低浓度抗茎抗体介导的保护依赖于 Fc-Fc 受体 (FcR) 相互作用；因此，抗体同种型决定了抗茎抗体在较低浓度下的保护活性。目前的提议是对分子机制进行多中心研究，这些分子机制可用于提供针对流感病毒的广泛保护。 我们的项目包括：1) 精确绘制介导病毒中和的病毒 HA 和神经氨酸酶糖蛋白上的表位，并剖析它们实现中和的机制。 2) 使用嵌合流感病毒蛋白进行免疫研究，旨在鉴定能够介导广谱体液免疫的结构元件。 3) 描述Fc-FcR相互作用在病毒中和中的作用。 4) 在人类受试者中研究如何在疫苗接种过程中引发具有有利 Fc 结构域的抗体。 5)人类B细胞针对流感抗原的特异性自然进化的研究。 6) 鉴定引发广谱抗流感体液免疫的流感抗原暴露的特定序列。总的来说，我们的目的是更好地了解针对流感病毒表面蛋白的广泛保护性体液免疫反应的机制，从而为推进新一代广泛保护性流感病毒疫苗和基于抗体的疗法制定蓝图。